Search

Search Constraints

You searched for: Author/Creator Hitre, Erika

Search Results

1. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Issue 11 (November 2022)

2. Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial. Issue 24 (19th October 2022)

3. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 8 (August 2021)

4. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2018)

5. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2018)

6. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. (27th October 2018)

7. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Issue 10294 (3rd July 2021)

8. Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy. Issue 6 (June 2015)

9. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. (September 2011)

10. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. (September 2011)